Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) have earned a consensus recommendation of “Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $146.06.

A number of brokerages have recently weighed in on GWPH. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Friday, October 6th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI began coverage on GW Pharmaceuticals PLC in a research report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price objective for the company. Finally, Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, August 8th.

Several large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new position in shares of GW Pharmaceuticals PLC in the 2nd quarter valued at about $70,128,000. Capital World Investors lifted its holdings in shares of GW Pharmaceuticals PLC by 6.3% in the 2nd quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock valued at $67,749,000 after acquiring an additional 40,000 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 0.4% in the 3rd quarter. Jennison Associates LLC now owns 492,480 shares of the biopharmaceutical company’s stock valued at $49,982,000 after acquiring an additional 1,759 shares during the last quarter. Redmile Group LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 33.8% in the 2nd quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after acquiring an additional 112,392 shares during the last quarter. Finally, Pictet Asset Management Ltd. lifted its holdings in shares of GW Pharmaceuticals PLC by 102.6% in the 3rd quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock valued at $36,056,000 after acquiring an additional 179,911 shares during the last quarter. 75.03% of the stock is owned by hedge funds and other institutional investors.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at $113.12 on Monday. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $136.95. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter in the previous year, the company posted ($0.05) EPS. sell-side analysts predict that GW Pharmaceuticals PLC will post -5.99 EPS for the current fiscal year.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/gw-pharmaceuticals-plc-gwph-receives-average-rating-of-buy-from-analysts/1681602.html.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.